Volume 24, Issue 2, February 2022

Reviews

Editor's Choice

Relationship between genetically determined telomere length and glioma risk

Charlie N Saunders and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 171–181, https://doi.org/10.1093/neuonc/noab208

• Abstract
• View article
• Supplementary data

Editorial

Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma

Linda Kachuri and Kyle M Walsh

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 182–183, https://doi.org/10.1093/neuonc/noab260

• Extract
• View article

Reviews

Extracellular vesicles: The key for precision medicine in glioblastoma

Massimiliano Del Bene and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 184–196, https://doi.org/10.1093/neuonc/noab229

• Abstract
• View article

Basic and Translational Investigations

Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles

Nils Ludwig and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 197–209, https://doi.org/10.1093/neuonc/noab153

• Abstract
• View article
• Supplementary data

Editorial

How mutant isocitrate dehydrogenase orchestrates immune cells

Lukas Bunse and Michael Platten

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 210–212, https://doi.org/10.1093/neuonc/noab266

• Extract
• View article

Basic and Translational Investigations

The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis

Cedric Tehranian and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 213–225, https://doi.org/10.1093/neuonc/noab159

• Abstract
• View article
• Supplementary data

Editorial

Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?

Agata M Kieliszek and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 226–228, https://doi.org/10.1093/neuonc/noab267

• Extract
• View article

Basic and Translational Investigations

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress

Pratibha Sharma and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 229–244, https://doi.org/10.1093/neuonc/noab175

• Abstracts
• View article
• Supplementary data

Editorial

Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas

Jing Wu

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 245–246, https://doi.org/10.1093/neuonc/noab265

• Extract
• View article

Basic and Translational Investigations

The use of external control data for predictions and futility interim analyses in clinical trials

Steffen Ventz and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 247–256, https://doi.org/10.1093/neuonc/noab141

• Abstract
• View article
• Supplementary data

Editorial

External controls to improve on glioblastoma clinical trials

Annette M Molinaro

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 257–258, https://doi.org/10.1093/neuonc/noab251

• Extract
• View article

Basic and Translational Investigations

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice

Pavlina Chuntova and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 259–272, https://doi.org/10.1093/neuonc/noab182

• Abstract
• View article
• Supplementary data

Pediatric Neuro-Oncology

Editor's Choice

Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma

Kent A Riemondy and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 273–286, https://doi.org/10.1093/neuonc/noab135

• Abstract
• View article
• Supplementary data

Editorial

Faraway, so close: Intratumoral heterogeneity of medulloblastoma subgroups

Livia Garzia

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 287–288, https://doi.org/10.1093/neuonc/noab281

• Extract
• View article

Pediatric Neuro-Oncology

Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors

Jian Peng and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 289–299, https://doi.org/10.1093/neuonc/noab151

• Abstract
• View article
• Supplementary data

Editorial

The data behind the image—Deep learning and its potential impact in neuro-oncological imaging

Birgit Ertl-Wagner and Farzad Khalvati

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 300–301, https://doi.org/10.1093/neuonc/noab249

• Extract
• View article

Clinical Investigations

Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas

Gi-Ming Wang and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 302–310, https://doi.org/10.1093/neuonc/noab199

• Abstract
• View article
• Supplementary data

Editorial

Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival

Judith Schwartzbaum and Randall Harris

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 311–312, https://doi.org/10.1093/neuonc/noab250

• Extract
• View article

Clinical Investigations

EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations

Isabelle Beuchat and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 313–325, https://doi.org/10.1093/neuonc/noab174

• Abstract
• View article
• Supplementary data

Letter to the Editor

Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium

Karlijn de Joode and others

Neuro-Oncology, Volume 24, Issue 2, February 2022, Pages 326–328, https://doi.org/10.1093/neuonc/noab258

• Extract
• View article
• Supplementary data

Society News

Forthcoming Meetings

Neuro-Oncology, Volume 24, Issue 2, February 2022, Page 329, https://doi.org/10.1093/neuonc/noac002

• Extract
• View article